Table 1.
Current trials with PARP inhibitor and immunotherapy combination
| Combination | Trial | Population | |
|---|---|---|---|
| olaparib + durvalumab | NCT03594396 | Phase I/II | Resectable stage II/III TNBC |
| MEDIPAC (NCT03772561) | Phase I | Advanced or metastatic solid tumors | |
| NCT03842228 | Phase I | DDR-mutated unresectable, advanced or metastatic solid tumors | |
| NCT03775486 | Phase II | Metastatic NSCLC | |
| NCT03579784 | Phase II | Unresectable or recurrent gastric carcinoma | |
| NCT03810105 | Phase II | Recurrent prostate cancer | |
| DOLAF (NCT04053322) | Phase II | Locally advanced or metastatic ER+ HER2- breast cancer | |
| DAPPER (NCT03851614) | Phase II | Locally advanced or metastatic MMR proficient CRC, pancreatic adenocarcinoma or leiomyosarcoma | |
| DOMEC (NCT03951415) | Phase II | Recurrent, refractory or metastatic endometrial cancer or carcinosarcoma of the endometrium | |
| DORA (NCT03167619) | Phase II | Locally advanced or metastatic platinum-treated TNBC | |
| MEDIOLA (NCT02734004) | Phase II | gBRCAm platinum-sensitive ovarian cancer; gBRCAm HER2- breast cancer; platinum-resistant relapsed gastric cancer | |
| NCT03801369 | Phase II | Metastatic TNBC | |
| BAYOU (NCT03459846) | Phase II | Advanced or metastatic platinum-ineligible urothelial carcinoma | |
| NCT02484404 | Phase II | Advanced, recurrent or metastatic ovarian, TNBC, lung, prostate, CRC or solid tumors | |
| NEODURVARIB (NCT03534492) | Phase II | Resectable urothelial cancer | |
| DUO-O (NCT03737643) | Phase III | Newly diagnosed advanced ovarian, fallopian tube or primary peritoneal carcinoma or carcinosarcoma | |
| DUO-E (NCT04269200) | Phase III | Newly diagnosed advanced or recurrent endometrial carcinoma | |
| olaparib + pembrolizumab | KEYNOTE-365 (NCT02861573) | Umbrella study | Previously treated mCRPC |
| olaparib + tremelimumab | NCT02571725 | Phase I | BRCA1/2 mutated recurrent ovarian cancer |
| olaparib + tremelimumab + durvalumab | NCT02953457 | Phase I/II | DDR mutated recurrent ovarian, fallopian tube or primary peritoneal cancer |
| niraparib + pembrolizumab | TOPACIO-KEYNOTE 162 (NCT02657889) | Phase II | Advanced or metastatic TNBC or platinum-resistant ovarian cancer |
| niraparib + PD-1 inhibitor | NCT03308942 | Phase II | Locally advanced or metastatic NSCLC |
| niraparib + TSR-042 niraparib + TSR-042 + platinum-based therapy | NCT03307785 NCT03602859 | Phase I/II Phase III | Solid tumors Nonmucinous epithelial ovarian cancer |
| niraparib + atezolizumab | ANITA (NCT03598270) | Phase III | Recurrent ovarian, fallopian tube, or primary peritoneal carcinoma |
| rucaparib + nivolumab | NCT03572478 | Phase I/II | mCRPC or recurrent endometrial cancer |
| ATHENA (NCT03522246) | Phase III | Front line ovarian cancer | |
| CheckMate 9KD (NCT03338790) | Phase III | mCRPC | |
| rucaparib + atezolizumab | ARIANES (NCT04276376) | Phase II | DDR-deficient or platinum sensitive solid tumors |
| rucaparib + atezolizumab | EndoBARR (NCT03694262) | Phase II | Recurrent progressive endometrial carcinoma |
| talazoparib + avelumab | Javelin PARP Medley (NCT03330405) | Phase Ib/II | Previously treated advanced solid tumors |
| Javelin BRCA/ATM (NCT03565991) | BRCA/ATM-mutant solid tumors | ||
| Javelin BRCA/ATM (NCT03637491) | Ras-mutant solid tumors | ||
| Javelin Ovarian PARP 100 (NCT03642132) | Phase III | Front line ovarian cancer | |
| BGB-A317 + BGB-290 | NCT02660034 | Basket study | Ovarian cancer, TNBC, mCRPC, bladder cancer, SCLC, HER2 (−) gastric cancer, pancreatic cancer, other solid tumors |
| veliparib + atezolizumab | NCT02849496 | HER2 (−), BRCA-mutant TNBC | |
| pamiparib + tislelizumab | NCT02660034 | Phase I | Previously treated advanced solid tumors |
Abbreviations: MMR (mismatch repair), CRC (colorectal cancer), mCRPC (metastatic castration-resistant prostate cancer), TNBC (triple-negative breast cancer), SCLC (small cell lung cancer)